NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

液體活檢研究工具,服務和診斷的全球市場

Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets

出版商 BCC Research 商品編碼 997078
出版日期 內容資訊 英文 345 Pages
訂單完成後即時交付
價格
液體活檢研究工具,服務和診斷的全球市場 Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets
出版日期: 2021年03月23日內容資訊: 英文 345 Pages
簡介

在預測期內,全球液體活檢市場預計將以38.5%的複合年增長率增長,從2020年的38億美元增長到2025年的196億美元。

預計用於癌症的液體活檢領域將增長50.7%,從2020年的17億美元增長到2025年的136億美元。此外,非癌症液體活檢行業預計將以23.5%的複合年增長率增長,從2020年的21億美元增長到2025年的61億美元。

本報告調查了全球液體活檢市場,定義並概述了市場,分析了新的冠狀病毒感染(COVID-19)和其他市場影響因素,技術分析以及市場規模的變化,總結了各種預測,細目分類類別,例如臨床類別,平台,用途和地區,競爭環境以及主要公司的概況。

第1章簡介

第2章摘要要點

第3章概述

  • 報告範圍
  • 液體活檢和常規活檢
  • 市場
  • 生長促進劑
  • 主要趨勢
  • 行業

第4章技術背景

  • 液體活檢生物標誌物
  • 癌症基因組學
  • 非侵入性產前檢查(NIPT)
  • 循環腫瘤細胞技術(CTC)
  • CTC工作流程
  • 細胞分離技術
  • CTC樣品製備技術
  • CTC下游分析技術
  • 液體活檢與常規活檢的比較
  • 癌症篩查
  • 產前檢查

第5章液體活檢倡議

第6章液體活檢的用途

  • 癌症
  • 精準醫學
  • 液體活檢生物標誌物
  • 生殖健康
  • 移植診斷

第7章液體活檢行業

  • 測序設備
  • 第三代測序
  • 測序信息學
  • PCR
  • 液滴數位PCR
  • CTC捕獲/檢測
  • 液體活檢分析
  • 液體活檢癌篩查/早期發現
  • 非侵入性產前檢查(NIPT)

第8章收購/戰略聯盟

第9章液體活檢市場

  • 市場增長動力
  • 主要利益相關者的角色
  • 新的 "大型" 應用程序
  • COVID-19環境
  • 中國的重要性日益提高
  • COVID-19的影響
  • 市場規模的趨勢和預測:按臨床類別
  • 市場規模的趨勢和預測:按分析目的
  • 市場規模的趨勢和預測:按生物標誌物類型
  • 市場規模的趨勢和預測:通過分析平台
  • NIPT市場趨勢/預測
  • 市場規模的趨勢和預測:癌症應用
  • 市場規模的趨勢和預測:按癌症站點劃分
  • 市場規模的趨勢和預測:按分析目的
  • 市場規模的趨勢和預測:按生物標誌物類別
  • 市場規模的趨勢和預測:通過分析方法
  • 市場規模趨勢/預測:移植診斷應用
  • 市場規模的趨勢和預測:按地區

第10章專利審查/新進展

第11章公司簡介

  • 4D LIFETEC AG
  • ACCURAGEN INC.
  • ACCUROME HEALTH INC.
  • ADAPTIVE BIOTECHNOLOGIES INC.
  • ADVANCED CELL DIAGNOSTICS INC.
  • AGILENT TECHNOLOGIES INC.
  • AKADEUM LIFE SCIENCES
  • ALCEDIAG
  • AMOY DIAGNOSTICS CO., LTD.
  • ANGLE PLC
  • APOCELL INC.
  • APOSTLE INC.
  • ARCEDI BIOTECH APS
  • ARCHER DX
  • ARUP LABORATORIES
  • ASURAGEN INC.
  • AVIVA BIOMED INC.
  • AVIVA BIOSCIENCES
  • BARD1 LIFE SCIENCES LTD.
  • BASE GENOMICS
  • BAYLOR GENETICS
  • BECTON, DICKINSON AND CO.
  • BERRY GENOMICS CO., LTD.
  • BGI SHENZHEN
  • BIOCARTIS NV
  • BIOCEPT INC.
  • BIODESIX INC.
  • BIOFLUIDICA INC.
  • BIOGAZELLE
  • BIOLIDICS LTD.
  • BIOLOGICAL DYNAMICS INC.
  • BIOPROGNOS SL
  • BIO-RAD LABORATORIES INC.
  • BIO-TECHNE CORP.
  • BITBIOME INC.
  • BLUESTAR GENOMICS INC.
  • BURNING ROCK BIOTECH LTD.
  • C2I GENOMICS
  • CADEX GENOMICS CORP.
  • CAMBRIDGE EPIGENETIX
  • CANCER GENETICS INC.
  • CANEXIA HEALTH
  • CAPIO BIOSCIENCES
  • CAPTIS DIAGNOSTICS INC.
  • CAREDX INC.
  • CARIS LIFE SCIENCE
  • CEGAT GMBH
  • CELLMAX LIFE
  • CELL MICROSYSTEMS INC.
  • CELSEE DIAGNOSTICS
  • CELTIC B.V.
  • CHRONIX BIOMEDICAL
  • CIRCULOGENE THERANOSTICS
  • CLARET BIOSCIENCE
  • CLINICAL GENOMICS TECHNOLOGIES
  • CODIAK BIOSCIENCES
  • CRADLE GENOMICS
  • CYCLOMICS
  • CYGNUS BIOSCIENCES CO., LTD.
  • CYTOTRACK APS
  • DANAHER CORP.
  • DATAR CANCER GENETICS LTD.
  • DELFI DIAGNOSTICS
  • DIACARTA INC.
  • DIAGNOLOGIX LLC
  • DIAGNOMICS
  • DIAMIR BIO
  • DNALYTICS
  • DNANEXUS INC.
  • DOVETAIL GENOMICS LLC
  • EARLYDX INC.
  • EDP BIOTECH CORP.
  • EPIC SCIENCES INC.
  • EPIGENOMICS AG
  • EUROFINS SCIENTIFIC
  • EXACT SCIENCES CORP.
  • EXOSOME SCIENCES INC.
  • EXOPERT
  • EXOSOMICS SPA
  • EZLIFE BIO INC.
  • FABRIC GENOMICS
  • FLUXION BIOSCIENCES INC.
  • FREENOME INC.
  • GENAPSYS INC.
  • GENECAST INC.
  • GENEDX INC.
  • GENETRON HEALTH TECHNOLOGIES
  • GENESEQ BIOSCIENCES PTY LTD.
  • GENEXOSOME TECHNOLOGIES INC.
  • GENOMICTREE
  • GENOMONCOLOGY
  • GENOSABER
  • GENOSITY
  • GRAIL INC.
  • GUARDANT HEALTH INC.
  • HTG MOLECULAR DIAGNOSTICS INC.
  • IDL BIOTECH
  • ID SOLUTIONS
  • ILLUMINA INC.
  • IMMUNOVIA AB
  • INCELLDX INC.
  • INEX INNOVATE PTE. LTD.
  • INIVATA LTD.
  • INTERPACE BIOSCIENCES INC.
  • INVITAE INC.
  • INVIVOSCRIBE INC.
  • JABREHOO MEDTECH CO., LTD.
  • JBS SCIENCE INC.
  • KONINKLIJKE PHILIPS N.V.
  • LABORATORY CORP. OF AMERICA INC.
  • LABRINTH BIOTECH INC.
  • LARIAT BIOSCIENCES INC.
  • LEXENT BIO INC.
  • LIQUID BIOPSY LABS
  • LUCENCE DIAGNOSTICS PTE. LTD.
  • LUNGLIFE AI INC.
  • MDNA LIFE SCIENCES INC.
  • MDXHEALTH INC.
  • MEDGENOME INC.
  • MENARINI SILICON BIOSYSTEMS SPA
  • MERCK KGAA
  • MICAREO RARE CELL DIAGNOSTICS
  • MIR SCIENTIFIC
  • MIRXES
  • MURSLA LTD
  • MUTANTDX
  • MYRIAD GENETICS INC.
  • NAMOCELL INC.
  • NANOSTRING TECHNOLOGIES INC.
  • NANOVIEW BIOSCIENCES INC.
  • NATERA INC.
  • NAVERIS INC.
  • NEOGENOMICS LABORATORIES
  • NEO NEW ONCOLOGY GMBH
  • NEW ENGLAND BIOLABS
  • NEW HORIZON HEALTH LTD.
  • NIPD GENETICS
  • NOVIGENIX SA
  • NOVOGENE CO., LTD.
  • NRICHDX INC.
  • NUCLEIX
  • NUPROBE INC.
  • NX PRENATAL INC.
  • ONCIMMUNE HOLDINGS PLC
  • ONCOCYTE CORP.
  • ONCODNA S.A.
  • ONCOLAB DIAGNOSTICS GMBH
  • OPKO HEALTH
  • OTRACES INC.
  • OXFORD NANOPORE TECHNOLOGIES LTD.
  • PACIFIC BIOSCIENCES OF CALIFORNIA INC.
  • PANGAEA ONCOLOGY
  • PERSONAL GENOME DIAGNOSTICS INC.
  • PERSUASIVE
  • PFDENA INC.
  • PHASE SCIENTIFIC
  • PIERIANDX
  • PREDICINE INC.
  • PROVISTA DIAGNOSTICS INC.
  • QCDX LLC
  • QIAGEN NV
  • QUANTAPORE INC.
  • QUANTGENE INC.
  • QUANTUM BIOSYSTEMS INC.
  • QUANTUMDX
  • QUEST DIAGNOSTICS INC.
  • RARECELLS SAS
  • RAVGEN
  • REAL TIME GENOMICS INC.
  • RESOLUTION BIOSCIENCE INC.
  • ROCHE HOLDING AG
  • SAGA DIAGNOSTICS AB
  • SANOMICS LTD.
  • SANO GENETICS
  • SCREENCELL
  • SEEKIN
  • SEER INC.
  • SERACARE LIFE SCIENCES INC.
  • SEQUENCING.COM
  • SEVEN BRIDGES GENOMICS INC.
  • SINGLE TECHNOLOGIES
  • SINGLERA GENOMICS INC.
  • SMARTCACTCH
  • SOMALOGIC INC.
  • STAGE ZERO LIFE SCIENCES
  • STILLA TECHNOLOGIES
  • STRAND LIFE SCIENCES PVT., LTD.
  • STRATA ONCOLOGY
  • STRATOS GENOMICS INC.
  • SYAPSE
  • SYSMEX INOSTICS GMBH
  • TAILAI BIOSCIENCES CO., LTD.
  • TAKARA BIO INC.
  • TELEXOS GMBH
  • THERMO FISHER SCIENTIFIC INC.
  • TWINSTRAND BIOSCIENCES
  • TYMORA ANALYTICAL OPERATIONS LLC
  • UBIQUITY GENOMICS INC.
  • UNIVERSAL DIAGNOSTICS SL
  • VELA DIAGNOSTICS
  • VERACYTE
  • VOLITIONRX
  • VORTEX BIOSCIENCES
  • XING TECHNOLOGIES LLC
  • YIKON GENOMICS CO., LTD.
  • YOURGENE HEALTH PLC
目錄
Product Code: BIO150D

Highlights:

The global market for liquid biopsy should increase from $3.8 billion in 2020 to $19.6 billion by 2025, at a compound annual growth rate (CAGR) of 38.5% during the period of 2020-2025.

The global market for liquid biopsy for cancer applications should increase from $1.7 billion in 2020 to $13.6 billion by 2025, at a CAGR of 50.7% during the period of 2020-2025.

The global market for liquid biopsy for non-cancer applications should increase from $2.1 billion in 2020 to $6.1 billion by 2025, at a CAGR of 23.5% during the period of 2020-2025.

Report Scope:

The scope of the report includes liquid biopsy technologies, applications, industry subsegments, biomarker technologies, major funding initiatives, patents and companies. The market sizes for liquid biopsy diagnostics are given for 2019, 2020 and 2025 (forecasted).

This report reviews liquid biopsy biomarkers and technologies and provides background on why liquid biopsy is increasingly viewed as a replacement for, or a companion to, tissue biopsy. The report then discusses several of the significant large-scale research initiatives that are contributing to liquid biopsy development. The key forces driving the market are enumerated.

The structures of several important industry subsectors, as well as major industry acquisitions and strategic alliances from January 2019 through January 2021, are reviewed. The industry subsectors that have been analyzed include DNA sequencing and instruments; long-read sequencing; sequencing informatics; PCR; droplet digital PCR; CTC capture and detection; liquid biopsy; cancer screening/early detection; and noninvasive prenatal screening.

The market for liquid biopsy diagnostics is analyzed in depth. The market is analyzed by -

  • Application (cancer, reproductive health, transplant);
  • Biomarker type, including circulating nucleic acids, circulating tumor cells, and other (extracellular vesicles, proteins);
  • Analysis platforms including NGS, PCR and other (microarray, Sanger sequencing, immunoassay, immunocytochemistry, and cell capture);
  • Analysis purpose (screening/early detection, diagnosis, therapy guidance, monitoring); and
  • Geography (North America, Europe, Asia-Pacific, Rest of World).
  • Market data covers 2019, 2020 and 2025 (forecasted).

The report contains a large profile compilation of more than 200 companies in the liquid biopsy industry.

BCC Research provides a summary of the main industry acquisitions and strategic alliances from January 2019 through January 2021, including key alliance trends.

Report Includes:

  • 29 data tables and 56 additional tables
  • An overview of the global market for liquid biopsy research tools, services and diagnostics
  • Estimation of the market size and analyses of global market trends, with data from 2019 and 2020, and projections of compound annual growth rates (CAGRs) through 2025
  • Characterization and quantification of market potential for liquid biopsy diagnostics by application, biomarker type, analysis platform, analysis purpose and geographical region
  • Discussion on significant large-scale research initiatives that are contributing to liquid biopsy market development
  • Examination of various conventional biopsy methods and information on how liquid biopsy enabling technologies address the issues and are gaining significant traction with key opinion leaders
  • Identification of market drivers, restraints and other forces influencing the growth of the liquid biopsy market
  • Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies
  • Review of patents and new developments in circulating tumor cell (CTC) technologies, exosome technologies, cell-free DNA technologies, and cancer biomarkers
  • Company profiles of major liquid biopsy market players, including Bard1 Life Sciences Ltd., Becton, Dickinson and Co. (BD), Bio-Rad Laboratories Inc., Danaher Corp., Exosome Sciences Inc., Qiagen NV and Roche Holding AG

Table of Contents

Chapter 1 Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Overview

  • Introduction
  • Scope of Report
  • Liquid Biopsy vs. Traditional Biopsy
  • Markets
  • Forces Driving Growth
  • Key Trends
  • Industry

Chapter 4 Technology Background

  • Liquid Biopsy Biomarkers
  • Cancer Genomics
  • Noninvasive Prenatal Testing (NIPT)
  • Circulating Tumor Cell Technologies (CTCs)
  • CTC Workflow
  • Cell Isolation Technologies
  • CTC Sample Preparation Technologies
  • CTC Downstream Analysis Technologies
  • Comparison of Liquid Biopsy with Conventional Biopsy
  • Cancer Testing
  • Prenatal Testing

Chapter 5 Liquid Biopsy Initiatives

  • Introduction
  • Liquid Biopsy-Related Research and Development
  • Initiatives and Programs
  • Population Sequencing Projects

Chapter 6 Liquid Biopsy Applications

  • Introduction
  • Cancer Applications
  • Precision Medicine
  • Liquid Biopsy Biomarkers
  • Cancer Market Segments
  • Reproductive Health Applications
  • Transplant Diagnostic Applications

Chapter 7 Liquid Biopsy Industry

  • Introduction
  • Sequencing Instruments Industry
  • Third-Generation Sequencing Industry
  • Sequencing Informatics Industry
  • PCR Industry
  • Droplet Digital PCR Industry
  • CTC Capture and Detection Industry
  • Liquid Biopsy Assay Industry
  • Liquid Biopsy Cancer Screening/Early Detection Industry
  • Noninvasive Prenatal Testing (NIPT) Industry

Chapter 8 Industry Acquisitions and Strategic Alliances

  • Acquisitions
  • Strategic Alliances
  • Key Trends
  • Summary of Alliances

Chapter 9 Markets for Liquid Biopsy

  • Forces Driving Growth in the Markets for Liquid Biopsy
  • Precision Medicine
  • Rise of Tissue-Agnostic Drugs
  • Genomics Initiatives
  • Clinical Need for Better Diagnostics
  • Role of Key Stakeholders
  • Emerging "Mega" Applications
  • COVID-19 Environment
  • Rise in the Importance of China
  • Impact of COVID-19 on the Global Market for Liquid Biopsy
  • Global Market for Liquid Biopsy by Clinical Category
  • Global Market for Liquid Biopsy by Purpose of Analysis
  • Global Market for Liquid Biopsy by Biomarker Type
  • Global Market for Liquid Biopsy by Analysis Platform
  • Global Market for Noninvasive Prenatal Testing
  • Global Market for Liquid Biopsy in Cancer Applications
  • Global Market for Liquid Biopsy for Cancer Diagnostics by Cancer Site
  • Global Market for Liquid Biopsy in Cancer Applications by Purpose of Analysis
  • Global Market for Liquid Biopsy in Cancer Applications by Biomarker Class
  • Global Market for Liquid Biopsy in Cancer Applications by Analysis Method
  • Global Market for Liquid Biopsy for Transplant Diagnostics
  • Global Market for Liquid Biopsy by Geographic Region

Chapter 10 Patent Review/New Developments

  • Patents on Circulating Tumor Cell (CTC) Technologies
  • Patents on Exosome Technologies
  • Patents on Cell-Free DNA Technologies
  • Biomarker-Related Patents
  • Patent Considerations for the Use of Artificial Intelligence in Cancer Diagnostics
  • Lawsuits on Liquid Biopsy Patents

Chapter 11 Company Profiles

  • 4D LIFETEC AG
  • ACCURAGEN INC.
  • ACCUROME HEALTH INC.
  • ADAPTIVE BIOTECHNOLOGIES INC.
  • ADVANCED CELL DIAGNOSTICS INC.
  • AGILENT TECHNOLOGIES INC.
  • AKADEUM LIFE SCIENCES
  • ALCEDIAG
  • AMOY DIAGNOSTICS CO., LTD.
  • ANGLE PLC
  • APOCELL INC.
  • APOSTLE INC.
  • ARCEDI BIOTECH APS
  • ARCHER DX
  • ARUP LABORATORIES
  • ASURAGEN INC.
  • AVIVA BIOMED INC.
  • AVIVA BIOSCIENCES
  • BARD1 LIFE SCIENCES LTD.
  • BASE GENOMICS
  • BAYLOR GENETICS
  • BECTON, DICKINSON AND CO.
  • BERRY GENOMICS CO., LTD.
  • BGI SHENZHEN
  • BIOCARTIS NV
  • BIOCEPT INC.
  • BIODESIX INC.
  • BIOFLUIDICA INC.
  • BIOGAZELLE
  • BIOLIDICS LTD.
  • BIOLOGICAL DYNAMICS INC.
  • BIOPROGNOS SL
  • BIO-RAD LABORATORIES INC.
  • BIO-TECHNE CORP.
  • BITBIOME INC.
  • BLUESTAR GENOMICS INC.
  • BURNING ROCK BIOTECH LTD.
  • C2I GENOMICS
  • CADEX GENOMICS CORP.
  • CAMBRIDGE EPIGENETIX
  • CANCER GENETICS INC.
  • CANEXIA HEALTH
  • CAPIO BIOSCIENCES
  • CAPTIS DIAGNOSTICS INC.
  • CAREDX INC.
  • CARIS LIFE SCIENCE
  • CEGAT GMBH
  • CELLMAX LIFE
  • CELL MICROSYSTEMS INC.
  • CELSEE DIAGNOSTICS
  • CELTIC B.V.
  • CHRONIX BIOMEDICAL
  • CIRCULOGENE THERANOSTICS
  • CLARET BIOSCIENCE
  • CLINICAL GENOMICS TECHNOLOGIES
  • CODIAK BIOSCIENCES
  • CRADLE GENOMICS
  • CYCLOMICS
  • CYGNUS BIOSCIENCES CO., LTD.
  • CYTOTRACK APS
  • DANAHER CORP.
  • DATAR CANCER GENETICS LTD.
  • DELFI DIAGNOSTICS
  • DIACARTA INC.
  • DIAGNOLOGIX LLC
  • DIAGNOMICS
  • DIAMIR BIO
  • DNALYTICS
  • DNANEXUS INC.
  • DOVETAIL GENOMICS LLC
  • EARLYDX INC.
  • EDP BIOTECH CORP.
  • EPIC SCIENCES INC.
  • EPIGENOMICS AG
  • EUROFINS SCIENTIFIC
  • EXACT SCIENCES CORP.
  • EXOSOME SCIENCES INC.
  • EXOPERT
  • EXOSOMICS SPA
  • EZLIFE BIO INC.
  • FABRIC GENOMICS
  • FLUXION BIOSCIENCES INC.
  • FREENOME INC.
  • GENAPSYS INC.
  • GENECAST INC.
  • GENEDX INC.
  • GENETRON HEALTH TECHNOLOGIES
  • GENESEQ BIOSCIENCES PTY LTD.
  • GENEXOSOME TECHNOLOGIES INC.
  • GENOMICTREE
  • GENOMONCOLOGY
  • GENOSABER
  • GENOSITY
  • GRAIL INC.
  • GUARDANT HEALTH INC.
  • HTG MOLECULAR DIAGNOSTICS INC.
  • IDL BIOTECH
  • ID SOLUTIONS
  • ILLUMINA INC.
  • IMMUNOVIA AB
  • INCELLDX INC.
  • INEX INNOVATE PTE. LTD.
  • INIVATA LTD.
  • INTERPACE BIOSCIENCES INC.
  • INVITAE INC.
  • INVIVOSCRIBE INC.
  • JABREHOO MEDTECH CO., LTD.
  • JBS SCIENCE INC.
  • KONINKLIJKE PHILIPS N.V.
  • LABORATORY CORP. OF AMERICA INC.
  • LABRINTH BIOTECH INC.
  • LARIAT BIOSCIENCES INC.
  • LEXENT BIO INC.
  • LIQUID BIOPSY LABS
  • LUCENCE DIAGNOSTICS PTE. LTD.
  • LUNGLIFE AI INC.
  • MDNA LIFE SCIENCES INC.
  • MDXHEALTH INC.
  • MEDGENOME INC.
  • MENARINI SILICON BIOSYSTEMS SPA
  • MERCK KGAA
  • MICAREO RARE CELL DIAGNOSTICS
  • MIR SCIENTIFIC
  • MIRXES
  • MURSLA LTD
  • MUTANTDX
  • MYRIAD GENETICS INC.
  • NAMOCELL INC.
  • NANOSTRING TECHNOLOGIES INC.
  • NANOVIEW BIOSCIENCES INC.
  • NATERA INC.
  • NAVERIS INC.
  • NEOGENOMICS LABORATORIES
  • NEO NEW ONCOLOGY GMBH
  • NEW ENGLAND BIOLABS
  • NEW HORIZON HEALTH LTD.
  • NIPD GENETICS
  • NOVIGENIX SA
  • NOVOGENE CO., LTD.
  • NRICHDX INC.
  • NUCLEIX
  • NUPROBE INC.
  • NX PRENATAL INC.
  • ONCIMMUNE HOLDINGS PLC
  • ONCOCYTE CORP.
  • ONCODNA S.A.
  • ONCOLAB DIAGNOSTICS GMBH
  • OPKO HEALTH
  • OTRACES INC.
  • OXFORD NANOPORE TECHNOLOGIES LTD.
  • PACIFIC BIOSCIENCES OF CALIFORNIA INC.
  • PANGAEA ONCOLOGY
  • PERSONAL GENOME DIAGNOSTICS INC.
  • PERSUASIVE
  • PFDENA INC.
  • PHASE SCIENTIFIC
  • PIERIANDX
  • PREDICINE INC.
  • PROVISTA DIAGNOSTICS INC.
  • QCDX LLC
  • QIAGEN NV
  • QUANTAPORE INC.
  • QUANTGENE INC.
  • QUANTUM BIOSYSTEMS INC.
  • QUANTUMDX
  • QUEST DIAGNOSTICS INC.
  • RARECELLS SAS
  • RAVGEN
  • REAL TIME GENOMICS INC.
  • RESOLUTION BIOSCIENCE INC.
  • ROCHE HOLDING AG
  • SAGA DIAGNOSTICS AB
  • SANOMICS LTD.
  • SANO GENETICS
  • SCREENCELL
  • SEEKIN
  • SEER INC.
  • SERACARE LIFE SCIENCES INC.
  • SEQUENCING.COM
  • SEVEN BRIDGES GENOMICS INC.
  • SINGLE TECHNOLOGIES
  • SINGLERA GENOMICS INC.
  • SMARTCACTCH
  • SOMALOGIC INC.
  • STAGE ZERO LIFE SCIENCES
  • STILLA TECHNOLOGIES
  • STRAND LIFE SCIENCES PVT., LTD.
  • STRATA ONCOLOGY
  • STRATOS GENOMICS INC.
  • SYAPSE
  • SYSMEX INOSTICS GMBH
  • TAILAI BIOSCIENCES CO., LTD.
  • TAKARA BIO INC.
  • TELEXOS GMBH
  • THERMO FISHER SCIENTIFIC INC.
  • TWINSTRAND BIOSCIENCES
  • TYMORA ANALYTICAL OPERATIONS LLC
  • UBIQUITY GENOMICS INC.
  • UNIVERSAL DIAGNOSTICS SL
  • VELA DIAGNOSTICS
  • VERACYTE
  • VOLITIONRX
  • VORTEX BIOSCIENCES
  • XING TECHNOLOGIES LLC
  • YIKON GENOMICS CO., LTD.
  • YOURGENE HEALTH PLC

List of Tables

  • Summary Table : Global Market for Liquid Biopsy, by Disease Class, Through 2025
  • Table 1 : Liquid Biopsy Sample Types and Characteristics
  • Table 2 : Scope of Liquid Biopsy Report
  • Table 3 : Global Market for Liquid Biopsy, by Analysis Type, Through 2025
  • Table 4 : Forces Driving Growth in the Market for Liquid Biopsy
  • Table 5 : Key Trends in the Market for Liquid Biopsy
  • Table 6 : Liquid Biopsy Industry Subsectors
  • Table 7 : Liquid Biopsy Biomarker Classes
  • Table 8 : Single-Cell Analysis to Identify Cancer Driver Mutations
  • Table 9 : Genomics-Based Oncology Workflow
  • Table 10 : Unique Challenges of CTC Capture and Analysis
  • Table 11 : CTC Workflow
  • Table 12 : Cell Differentiators
  • Table 13 : Cell Isolation Technologies and Performance
  • Table 14 : CTC Sample Preparation Technologies
  • Table 15 : Single-Cell Analysis Technologies
  • Table 16 : Estimated Annual Solid Biopsy Procedures Performed in the U.S. for Selected Cancers, by Cancer Indication
  • Table 17 : Main Risks of Needle-Based Tissue Biopsies
  • Table 18 : Factors in Tissue Biopsy
  • Table 19 : Prenatal Invasive Testing Technologies
  • Table 20 : Invasive vs. Noninvasive Prenatal Technologies
  • Table 21 : Liquid Biopsy-Related Research and Development Initiatives and Programs
  • Table 22 : Single-Cell Core Research Facilities
  • Table 23 : Population Sequencing Projects
  • Table 24 : Source of Foreign Biomarkers for Liquid Biopsy Applications
  • Table 25 : Precision Medicine Driven by Common Cancer Genetic Mutations
  • Table 26 : Liquid Biopsy Biomarker Types
  • Table 27 : Market Segments of Liquid Biopsy in Cancer Applications
  • Table 28 : NIPT Screening Applications
  • Table 29 : Ethical Issues Associated with NIPT
  • Table 30 : Transplant Diagnostic Applications
  • Table 31 : Key Segments and Trends within the Liquid Biopsy Industry
  • Table 32 : Advanced Sequencing Industry Company Positioning
  • Table 33 : Long-Read Sequencing Industry
  • Table 34 : Sequencing Informatics Industry
  • Table 35 : PCR Companies
  • Table 36 : Advantages of Droplet Digital PCR
  • Table 37 : Digital PCR Liquid Biopsy Industry
  • Table 38 : Main Companies of CTC Separations Industry
  • Table 39 : Liquid Biopsy Assay Industry: Company Focus
  • Table 40 : Examples of NGS-Based Liquid Biopsy Market Differentiation
  • Table 41 : Multi-Cancer Screening Test Desired Features
  • Table 42 : Shed Rates of Various Cancers
  • Table 43 : Cancer Screening Liquid Biopsy Industry
  • Table 44 : Thrive Earlier Detection (Exact Sciences) Cancer Targets
  • Table 45 : Colorectal Cancer Early Detection/Screening Liquid Biopsy Industry
  • Table 46 : Key Clinical Trials for Single- and Multi-Cancer Liquid Biopsy Assays
  • Table 47 : Key Companies in the NIPT Industry
  • Table 48 : Acquisitions in the Liquid Biopsy Industry, January 2019-January 2021
  • Table 49 : Strategic Alliances in the Liquid Biopsy Industry, January 2019-January 2021
  • Table 50 : Key Forces Driving Growth of Liquid Biopsy and Implications
  • Table 51 : Global Market for Liquid Biopsy, by Clinical Category, Through 2025
  • Table 52 : Global Market for Liquid Biopsy, by Purpose of Analysis, Through 2025
  • Table 53 : Global Market for Liquid Biopsy, by Biomarker Type, Through 2025
  • Table 54 : FDA-Approved or CE-Marked Tests with Epigenetic Component
  • Table 55 : Global Market for Liquid Biopsy, by Analysis Platform, Through 2025
  • Table 56 : Global Market for NIPT, by Purpose of Analysis, Through 2025
  • Table 57 : Global Market for NIPT, by Risk Type, Through 2025
  • Table 58 : Global Market for NIPT Diagnostics, by Biomarker Class, Through 2025
  • Table 59 : Global Market for NIPT, by Analysis Method, Through 2025
  • Table 60 : Limitations of Solid Biopsy in Cancer Applications
  • Table 61 : Low-Frequency Mutation Detection
  • Table 62 : Global Market for Liquid Biopsy for Cancer Diagnostics, by Cancer Site, Through 2025
  • Table 63 : Five-Year Survival Rate for Ovarian Cancer
  • Table 64 : National Institutes of Health Liquid Biopsy Early Detection Initiative
  • Table 65 : Lung Cancer Liquid Biopsy Clinical Trials
  • Table 66 : Global Liquid Biopsy Cancer Market, by Purpose of Analysis, Through 2025
  • Table 67 : MRI and Liquid Biopsy Methods
  • Table 68 : Early Detection Tissue of Origin Approaches
  • Table 69 : Global Market for Liquid Biopsy in Cancer Applications, by Biomarker Class, Through 2025
  • Table 70 : Global Market for Liquid Biopsy in Cancer Applications, by Analysis Method, Through 2025
  • Table 71 : Global Market for Liquid Biopsy in Transplant Applications, by Organ Type, Through 2025
  • Table 72 : Transplant Procedures Performed in the U.S., by Organ, 2018-2020
  • Table 73 : Global Market for Liquid Biopsy in Transplant Applications, by Purpose of Analysis, Through 2025
  • Table 74 : Global Market for Liquid Biopsy in Transplant Applications, by Biomarker Class, Through 2025
  • Table 75 : Global Market for Liquid Biopsy in Transplant Applications, by Analysis Method, Through 2025
  • Table 76 : Global Market for Liquid Biopsy, by Region, Through 2025
  • Table 77 : Global Market for Liquid Biopsy in Cancer Applications, by Region, Through 2025
  • Table 78 : Global Market for Liquid Biopsy for NIPT, by Region, Through 2025
  • Table 79 : Global Market for Liquid Biopsy in Transplant Applications, by Region, Through 2025
  • Table 80 : Patent Activity on Circulating Tumor Cell Technologies, by Country/Region, January 2010-June 2020
  • Table 81 : Patent Activity on Exosome Technologies, by Country/Region, January 2010-December 2020
  • Table 82 : Patent Activity on Cell-Free DNA Technologies, by Country/Region, January 2010-December 2020
  • Table 83 : Patent Activity on Cancer Biomarkers, by Country/Region, January 2010-December 2020
  • Table 84 : Status of Liquid Biopsy Patent Disputes

List of Figures

  • Summary Figure : Global Market for Liquid Biopsy, by Disease Class, 2019-2025
  • Figure 1 : How Cancer Genomics Drives Liquid Biopsy